SLC5A2 and hydrops fetalis: Given the improvement in HF-associated outcomes seen with SGLT2 inhibitors, the results of DAPA-HF, and the recent Food and Drug Administration approval for the use of dapagliflozin in patients with HF with reduced ejection fraction, the coprescription of loop diuretic and SGLT2 inhibitors will become increasingly common,4,10 and therefore further mechanistic studies are required to understand their combined effects.